- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04154293
A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis
A Randomized, Parallel, Double-Blind, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Two Concentrations of Topical TMB-001 for the Treatment of Congenital Ichthyosis
The purpose of this study is to investigate the efficacy and safety of two concentrations of topically applied ointment formulation of isotretinoin called TMB-001 (0.05% and 0.1% isotretinoin) in subjects 9 years of age and older for the treatment of congenital ichthyosis (CI), including recessive X-linked ichthyosis (RXLI) and autosomal recessive congenital ichthyosis-lamellar ichthyosis (ARCI-LI) subtypes.
Funding Source FDA-OOPD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, parallel, double-blind, vehicle-controlled study to evaluate the safety and efficacy of two concentrations of topical TMB-001 for the treatment of CI in subjects with either the ARCI-LI or RXLI subtypes. The duration of treatment will be 12 weeks. Each subject will participate in the study for up to 24 weeks (including up to a 90-day Screening period). Eleven study centers from United States of America and Australia participated in this global study. Each subject participated in the study for up to 24 weeks (including up to a 90-day Screening period).
Eligible subjects were randomized (1:1:1) to one of 3 treatment groups:
- TMB-001, 0.05%, twice daily (bid)
- TMB-001, 0.1%, bid
- Vehicle Ointment (Control), 0%, bid
Subjects were evaluated on a monthly basis for safety and efficacy results over the 12- week treatment period. Efficacy was determined in 2 ways:
- VIIS (or Visual Index of Ichthyosis Severity) "treatment success" (VIIS-50) was defined as ≥ 50% reduction from Baseline for VIIS scaling score for the sum of the scores for 'VIIS body areas' that had a Baseline score ≥ 3). The proportion of subjects achieving VIIS-50 at Visit 6 at Week 12 relative to Baseline was the primary efficacy endpoint and time point used to compare the two active treatments to vehicle.
- The proportion of subjects achieving IGA (Investigator Global Assessment) treatment success will be the key secondary endpoint. For this endpoint, the IGA score was established as "treatment success" or "treatment failure" where "treatment success" is defined as at least a 2-grade decrease in severity score (for example, severe or score of 4 at baseline to mild or score of 2 at Visit 6) relative to Baseline at Visit 6 at week 12.
The safety analyses conducted were extent of exposure, changes in physical examinations and vital signs, blood and urine testing including urine pregnancy testing as indicated, local skin reactions (including burning/stinging, redness, erosions, and swelling) and other adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Queensland
-
Brisbane, Queensland, Australia, 4101
- Queensland Children's Hospital
-
-
Sydney
-
Kogarah, Sydney, Australia, NSW 2217
- Premier Specialists, The church
-
-
Victoria
-
Melbourne, Victoria, Australia, 3052
- Murdoch Children's Research Institute, RCH
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Medical Dermatology Specialists
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale Center for Clinical Investigation
-
-
Indiana
-
Plainfield, Indiana, United States, 46168
- The Indiana Clinical Trials Center
-
-
Louisiana
-
Metairie, Louisiana, United States, 70005
- Austin Institute for Clinical Research, Inc
-
-
Minnesota
-
New Brighton, Minnesota, United States, 55112
- Minnesota Clinical Study Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- The Children's Hospital of Philadelphia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is male or female, 9 years of age or older at Visit 2 (Baseline)
- Subject has provided written informed consent
- Females of child bearing potential must be surgically sterile or agree to 2 forms of birth control
- Subject has clinical diagnosis of Congenital Ichthyosis with genetic confirmation of subtype
- Subject has between 10% and 90% total BSA affected by Congenital Ichthyosis
- Subject has at least 2 VIIS assessment areas with a scaling score of 3 or greater
Exclusion Criteria:
- Subject has inflammatory skin diseases unrelated to ichthyosis
- Subject has used other prohibited topical treatments in the assessment areas within certain days from baseline
- Subject has used systemic retinoids within12 weeks of baseline
- Subject has untreated secondary infections
- Subject has lesions suspicious for skin cancer or untreated skin cancers
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Vehicle Ointment (Control)
Topical, BID (Twice daily)
|
Topical Vehicle Ointment
|
Experimental: TMB-001 Ointment, 0.05%
Topical, BID ( twice daily)
|
Topical Isotretinoin ointment
Other Names:
|
Experimental: TMB-001 Ointment, 0.1%
Topical, BID (Twice daily)
|
Topical Isotretinoin ointment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Reduction in Targeted Ichthyosis Severity Using the Visual Index for Ichthyosis Severity Measurement
Time Frame: 12 weeks
|
Number of subjects with Visual Index for Ichthyosis Severity (VIIS) treatment success, defined as 50% or greater decreased in VIIS scaling score
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With Reduction in Overall Ichthyosis Severity as Measured With Investigator Global Assessment
Time Frame: 12 weeks
|
Number of subjects with Investigator Global Assessment decrease in disease severity by at least 2 grades
|
12 weeks
|
Change in I-NRS (Itch-Numeric Rating Scale) From Baseline at Week 12
Time Frame: 12 weeks
|
Mean numeric Change from baseline in Itch-Numeric Rating Scale (I-NRS) at Week 12 for entire population.
I-NRS is an 11-point visual analogue scale scored based upon 0 being no itch and 10 being worst itch imaginable.
Subjects were asked to grade their itch on such a scale at each visit where I-NRS was administered.
A 4-point change from baseline is considered clinically significant
|
12 weeks
|
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 12
Time Frame: 12 weeks
|
Change from Baseline in Dermatology Life Quality Index (DLQI) at Week 12 in all adult subjects. The DLQI is validated in all subjects over age 16 years and is a 10-question questionnaire which requests information on how the dermatological condition affects different aspects of their life. Each question is scored on a 0-3 scale (0=no impact, 3=major impact) for a total possible maximal score of 30. Scores over 11 in adults are considered to indicate moderate impairment of quality of life due to the skin disease. A 4-point improvement from baseline is considered clinically significant |
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Alan M Mendelsohn, MD, Timber Pharmaceuticals
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 235-9051-202
- 1R01FD006079-01A1 (U.S. FDA Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Ichthyosis
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingAutosomal Recessive Congenital Ichthyosis | Epidermolytic IchthyosisFrance
-
Centre Hospitalier Universitaire de NiceUnknownLamellar IchthyosisFrance
-
Krystal Biotech, Inc.Active, not recruitingTGM-1 Related Autosomal Recessive Congenital IchthyosisUnited States
-
Krystal Biotech, Inc.Not yet recruitingAutosomal Recessive IchthyosisUnited States
-
Maastricht University Medical CenterRecruiting
-
Yale UniversityFoundation for Ichthyosis & Related Skin Types (FIRST)TerminatedIchthyosisUnited States
-
Northwestern UniversityIcahn School of Medicine at Mount SinaiCompletedNetherton Syndrome | Ichthyosis | Lamellar Ichthyosis | Autosomal Recessive Congenital Ichthyosis | Congenital Ichthyosiform Erythroderma | Epidermolytic IchthyosisUnited States
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
National Medical Research Center for Children's...RecruitingCongenital IchthyosisRussian Federation
-
Crown Laboratories, Inc.CompletedIchthyosis VulgarisUnited States
Clinical Trials on Vehicle
-
Haus BioceuticalsCompletedEczema | Atopic DermatitisIndia
-
PfizerCompleted
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
Instituto Universitario de Oftalmobiología Aplicada...Completed
-
LEO PharmaCompleted
-
Bausch Health Americas, Inc.Dow Pharmaceutical SciencesCompleted
-
Johns Hopkins Bloomberg School of Public HealthCompletedObesity | Childhood Obesity | Dietary Habits | Water; Lack of | Feeding Behavior | Mother-Child RelationsUnited States
-
Dr. Reddy's Laboratories LimitedSyneos Health; AccelovanceCompletedHead Lice InfestationUnited States
-
University of British ColumbiaUnknownCicatrix | Scar | Keloid | Hypertrophic Scar | Skin Graft Scar | Skin Graft Complications | Donor Site ComplicationCanada
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States